Interestingly, melanoma patients treated with BRAFi, such as dabrafenib, commonly develop fast-growing cSCC within weeks of treatment, driven by preexisting Hras mutations and paradoxical activation of the MAPK signalling pathway20–22. Here, HRAS is linked to melanoma.